DAPT in ACS: more evidence on choice of P2Y12 inhibitor

Ticagrelor compared with clopidogrel as part of dual-antiplatelet therapy (DAPT) is not associated with a significant difference in the risk of net adverse clinical events (NACE) in patients with acute coronary syndrome treated with PCI, research shows. A retrospective study of 31,290 propensity-matched pairs from two US databases and one South Korean database, found the ...

Already a member?

Login to keep reading.

© 2021 the limbic